228 related articles for article (PubMed ID: 28474138)
1. Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
Wang X; Ma C; Li P; Zhao F; Bi L
Clin Rheumatol; 2017 Jun; 36(6):1369-1377. PubMed ID: 28474138
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.
Świerkot J; Gruszecka K; Matuszewska A; Wiland P
Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):397-404. PubMed ID: 25837853
[TBL] [Abstract][Full Text] [Related]
3. Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1β-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Wang XT; Li P; Xu TS; Ding R; Zhang X; Bi LQ
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):44-50. PubMed ID: 27894399
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
[TBL] [Abstract][Full Text] [Related]
5. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
[TBL] [Abstract][Full Text] [Related]
6. Iguratimod: a new disease-modifying antirheumatic drug.
Mucke HA
Drugs Today (Barc); 2012 Sep; 48(9):577-86. PubMed ID: 23032798
[TBL] [Abstract][Full Text] [Related]
7. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Luo Q; Sun Y; Liu W; Qian C; Jin B; Tao F; Gu Y; Wu X; Shen Y; Xu Q
J Immunol; 2013 Nov; 191(10):4969-78. PubMed ID: 24123677
[TBL] [Abstract][Full Text] [Related]
8. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.
Briot K; Rouanet S; Schaeverbeke T; Etchepare F; Gaudin P; Perdriger A; Vray M; Steinberg G; Roux C
Joint Bone Spine; 2015 Mar; 82(2):109-15. PubMed ID: 25557658
[TBL] [Abstract][Full Text] [Related]
9. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
[TBL] [Abstract][Full Text] [Related]
10. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
Ishiguro N; Yamamoto K; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Hara M;
Mod Rheumatol; 2013 May; 23(3):430-9. PubMed ID: 22833377
[TBL] [Abstract][Full Text] [Related]
11. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
12. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
Yoshioka Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Kanda H; Takagi H; Ito T; Kato T; Saito K; Funahashi K; Asai S; Takemoto T; Terabe K; Asai N; Ishiguro N; Kojima T
Mod Rheumatol; 2016; 26(2):169-74. PubMed ID: 26140467
[TBL] [Abstract][Full Text] [Related]
13. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis.
Torikai E; Kageyama Y; Takahashi M; Nagano A
Mod Rheumatol; 2006; 16(6):350-4. PubMed ID: 17164995
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
[TBL] [Abstract][Full Text] [Related]
15. Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Shrestha S; Zhao J; Yang C; Zhang J
Clin Rheumatol; 2020 Jul; 39(7):2139-2150. PubMed ID: 32076916
[TBL] [Abstract][Full Text] [Related]
16. Iguratimod for the treatment of rheumatoid arthritis in Japan.
Tanaka K; Yamaguchi T; Hara M
Expert Rev Clin Immunol; 2015 May; 11(5):565-73. PubMed ID: 25797025
[TBL] [Abstract][Full Text] [Related]
17. Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate.
Hensvold AH; Joshua V; Li W; Larkin M; Qureshi F; Israelsson L; Padyukov L; Lundberg K; Defranoux N; Saevarsdottir S; Catrina AI
Arthritis Res Ther; 2015 Sep; 17(1):239. PubMed ID: 26337028
[TBL] [Abstract][Full Text] [Related]
18. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction:
Ishiguro N; Shibata K; Yoshimura A; Ikeuchi S; Ishii M
Mod Rheumatol; 2020 Jul; 30(4):633-639. PubMed ID: 31403345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
